Related Experiment Video
Updated: Mar 9, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab: 13 open questions after 20years of clinical use
Francesca Pavanello1, Emanuele Zucca1, Michele Ghielmini1
1Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.
Abstract:
Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but despite 20years of intensive use, it remains a drug with a number of still obscure characteristics and unanswered questions. These include the mechanism of action and of resistance, the optimal schedule, the interaction with chemotherapy, as well as predictive factors for response rate and duration. Despite being very well tolerated, the question of its long term side effects and the risks of the administration near to a pregnancy have only recently been addressed. Also the indications are still not all clear: rituximab induces remissions as a single agent and improves the effect of chemotherapy, but its use as maintenance or as a substitute for watch and wait is still debated. Also, it is still unclear if its efficacy derives at least partly by reducing the risk of histological transformation in indolent NHL and reducing the risk of CNS relapse in aggressive NHL. Finally, despite of 20years of research, it is still unclear if rituximab can be efficiently substituted by biosimilars or new anti-CD20 antibodies. In this review we address all these questions and analyze the literature addressing these aspects.
Insights
Rituximab is effective for B-cell lymphoproliferative diseases but requires further research into its mechanisms, optimal use, and long-term effects. This review addresses key unanswered questions regarding this important therapeutic antibody.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Rituximab has significantly improved outcomes in B-cell lymphoproliferative diseases.
- Despite extensive use, critical aspects of its application remain incompletely understood.
Purpose of the Study:
- To comprehensively review and address unresolved questions surrounding rituximab therapy.
- To analyze the existing literature on rituximab's mechanism of action, resistance, optimal scheduling, and long-term safety.
Main Methods:
- Literature review and analysis of published studies on rituximab in B-cell lymphoproliferative diseases.
- Synthesis of data concerning efficacy, safety, and emerging therapeutic strategies.
Main Results:
- Rituximab's precise mechanisms of action and resistance are still under investigation.
- Optimal dosing, combination with chemotherapy, and predictive factors for response require further clarification.
- Long-term safety, use in pregnancy, and role in maintenance or substitution strategies are debated.
Conclusions:
- Further research is essential to fully elucidate rituximab's properties and optimize its clinical application.
- Understanding these aspects will guide the development of biosimilars and novel anti-CD20 antibodies.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF